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ABSTRACT
NEURONAL TOXICITY OF HUMORAL FACTORS FROM PATIENTS WITH
DIABETIC NEUROPATHY AND MECHANISM OF NEURONAL DEATH ON
CULTURED ADRENERGIC NEURONS
STUDIES OF AUTOIMMUNE PATHOGENESIS IN DIABETIC NEUROPATHY

Dong Liu
Eastern V irginia Medical School/Old Dominion University, 1996
Director: Dr. Gary L. Pittenger

Diabetic neuropathy is an extremely common medical problem because of the high
frequency of diabetes and its complications. Diabetic neuropathy consists o f not one, but
many patterns of nerve injury, each potentially with its own discrete pathogenic
mechanisms. Evidence is accumulating that indicates autoimmunity plays a role in diabetic
peripheral neuropathy. However, the significance of immunopathogenesis of diabetic
neuropathy is as yet unclear.
Using the N1E-L15 mouse neuroblastoma cell line (NB) as a model of the
adrenergic autonomic neuron, we found that sera o f IDDM patients with neuropathy inhibit
growth and differentiation o f adrenergic neurons in culture (Pittenger et al, 1993; 1995).
Some sera were cytotoxic and caused neuronal death. Further characterization of the
inhibiting, or toxic, factor in EDDM patient serum indicated that it had the properties of an
immunoglobulin. The toxic factor was present in the immunoglobulin fraction, and was
pre-absorbed by neuroblastoma cells and protein A beads. Immunocytochemistry revealed
a specific cell-surface binding pattern of immunoglobulin IgG which suggested the
presence of an antibody recognizing antigens on the neuroblastoma cell surface. Moreover,
the inhibiting effect of IDDM serum could be reversed by heat inactivation, indicating the
possible involvement of complement.
Further investigation revealed that the neuronal death induced by EDDM serum
occurred through the programmed cell death

mechanism,

apoptosis,

4'
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which was

characterized by cell shrinkage, cytoplasm condensation and DNA fragmentation.

A

sustained increase of cytosolic calcium concentration was detected by Fura-2, a
fluorescence indicator, at an early stage after exposure to IDDM serum. Apoptosis-related
protein expression was also examined in our model. Fas, a cell-surface receptor, seemed
to be expressed at the N1E-115 cell surface and recognized by IDDM serum. Whether it
was the antigen involved in apoptotic cell death or whether other antigens were also
involved remains to be further determined.
In conclusion, autoimmune-related humoral factors in the semm from EDDM
patients with neuropathy had an ability to inhibit neuronal cell growth and differentiation, in
some cases inducing cell death by apoptosis in cultured adrenergic neurons. However,
because N1E-115 cell was a murine tumor cell line, the significance of the findings to
diabetic neuropathy and clinical correlation needs to be further evaluated. These studies
indicated that immunopathogenesis may play an important role in the development of
diabetic neuropathy in IDDM patients.
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Chapter 1. Background and Significance

CHAPTER I.

I

BACKGROUND AND SIGNIFICAMCE

1.1. Diabetic Neuropathy and its pathogenesis
Diabetic neuropathy develops as a significant complication in patients with all forms
of diabetes mellitus. Estimates of the prevalence of neuropathy in the population of patients
with diabetes range from 10-50% (Boulton et al., 1985; Newrick et al., 1986; Harati,
1992), dependent on the criteria used to define neuropathy. Diabetic neuropathy is an
insidious degenerative disease of peripheral nerves. The most common form, distal
symmetrical sensorimotor neuropathy, afflicts sensory, m otor and autonomic nerves. It has
a predilection for neurons with the longest axons and show s fiber loss in the more remote
nerve trunks. The loss o f sensation predisposes the patients to lesions, especially o f the
foot, potentially resulting in gangrene and amputation. In other cases, focal and multifocal
neuropathy are asymmetrical, and might affect cranial, trunk or limb innervation. Many of
the diabetic neuropathic syndromes are characterized by painful symptoms with a sensation
of burning and associated with troublesome hyperesthesia (Vinik et al., 1988; 1992; 1994;;
Brewster et al., 1994; Boulton et al., 1986).
Autonomic neuropathy is a serious component o f diabetic neuropathy, heralding
mortality rates o f 25-50% within 2-3 years o f diagnosis o f autonomic neuropathy (Vinik et
al., 1988, 1992; Ewing et al., 1976; 1982; O'Brien et al., 1986).

Diabetic autonomic

neuropathy may manifest as dysfunction of several different organ systems: cardiovascular,
gastrointestinal, genitourinary, sudomotor, and ocular.

The symptoms are important in

individual patients, but difficult to evaluate and quantitate, because they are often
nonspecific (Julius, 1991). Symptoms can occur as early as the first year after diagnosis,
presenting as a combination of the following: orthostatic hypotension, diminished
sweating, diarrhea or constipation, hypoglycemic unawareness, urinary dysfunction,
impotence, delayed gastric emptying, alternating bouts o f diarrhea and constipation,

•»
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bladder atony and/or exercise intolerance (Pfeifer et al., 1984; O'Brien et al., 1986).
Cardiac conduction abnormalities may lead to cardiorespiratory arrest and resting
tachycardia. Autonomic neuropathy is associated with an increased mortality from renal
failure and an increased frequency o f retinopathy and peripheral neuropathy (O'Brien et al.,
1991).
The most important pathological changes in diabetic neuropathy are loss of
myelinated and unmyelinated axons, demyelination and axonal degeneration (Dyck et al,
1986). Distal nerves are more affected than proximal nerves, as determined by postmortem
nerve fiber density (Chopra et al., 1971). Subtle changes at the nodes of Ranvier along
diabetic human nerve, including paranodal swelling and alterations o f Schwann cell
attachments, termed axo-glial dysjunction are described (Sima et al., 1988).
In contrast to other peripheral neuropathy, autonomic nerve damage is confined to
small, predominantly unmyelinated nerve fibers.

Pathologic changes in the autonomic

nervous system studied from postmortem samples of diabetic patients with severe
autonomic neuropathy reflect severe loss o f myelinated fibers and degeneration.

Adrenal

medullary fibrosis was found in a retrospective pathology study in EDDM patients with
long duration (Brown et al., 1989). Infiltration o f lymphocytes and macrophages is seen in
autonomic ganglia and in or around autonomic nerve bundles of unmyelinated nerve fibers,
suggesting that a different pathogenesis may be involved in the development o f autonomic
neuropathy in diabetes (Duchen et al., 1980).
Most discouraging, the cause o f diabetic neuropathy is uncertain and an effective
treatment has not been identified.

Several independent modifying factors and multiple

pathogenetic mechanisms, some of which have been researched extensively, may interact to
produce neuropathy (Ward, 1989). The current hypotheses include:
1.

Chronic hyperglycemia and/or insulin deficiency are the primary factors in the

causation of diabetic neuropathy (Winegrad et al., 1977).

There is evidence that the

incidence and severity of complications secondary to diabetes correlate with the degree of
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metabolic control (DCCT, 1993). Hyperglycemia results in intracellular accumulation of
toxic metabolic products such as sorbitol, fructose, galactitol and advanced glycosylation
end products. Increased polyol-pathway activity and decreased sodium dependent myo
inositol uptake content, reduced energy use and defective function of (Na, K)-ATPase have
been described (Greene et al., 1988; 1989; Stevens et al., 1993; 1994), ail of which may be
responsible for osmotic stress and diminished nerve conduction velocity. Impaired Na-KATPase activity also appears to be responsible for intracellular Na+ accumulation and
resultant localized axonal paranodal swelling that characterizes diabetic neuropathy in both
humans and laboratory animals (Dyck et al., 1988).
2. Depletion or alteration o f neurotrophic growth factors may cause neuronal
dysfunction in diabetes.

A variety o f neurotrophic factors are necessary for normal

growth, development, maintenance and regeneration o f the peripheral nervous system.
Physiological concentrations of insulin, IGF-I or IGF-II reversibly enhance neurite
outgrowth and increase the contents o f neurofilament, alpha-tubulin, and beta-tubulin
mRNAs in cultured human neuroblastoma SH-SY5Y cells (Wang et al, 1992; Recio et al,
1984). Neurotrophic factor accessibility and action may be diminished in diabetes due to
defective transport and post-receptor signal transduction or due to reduced levels of
circulating growth factors (Faradji et al., 1990; Schmidt et al., 1993).
3. Microvascular insufficiency may contribute to diabetic neuropathy. Endothelial
cell swelling and proliferation, as well as platelet aggregation resulting in vessel occlusion
have been noted in the pathogenesis o f diabetic neuropathy. The diabetic nerve is also
more susceptible to ischemia and death (Tuck et al., 1984; Dyck et al., 1986). Endoneurial
capillary density is significantly reduced in severely neuropathic diabetic patients when
compared with control subjects (Malik et al., 1989). It is possible that altered peripheral
blood flow leads to increased spontaneous activity in nociceptive afferent fibers that are
present in the axonal sprouts that characterize small fiber neuropathy (Boulton et al., 1986).
4. Autoimmunity may play an important role in the development of diabetic
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The awareness o f the immunological process as one o f the possible

pathogenetic mechanisms in diabetic neuropathy has increased, especially in EDDM
patients.

Although it has been questioned, immunological processes are strongly

associated with diabetic autonomic neuropathy, indicated by clinical, morphological,
serological and cellular observations (Sundkvist et al., 1994). A role for autoimmunity in
the pathogenesis o f diabetic neuropathy is as described below.

1.2.

The role of autoimmunity in diabetic neuropathy
IDDM is a chronic autoimmune disease with a long prodromal phase, during which

antibodies that react with islet cells are often present (Bottazzo et al., 1986). Autoimmunity
is a known factor in the pathogenesis of islet cell destruction (Herold et al., 1992; Boitard,
1992), but little is known of its role in the pathogenesis o f the neuropathy complications of
diabetes.
Because diabetic neuropathy in IDDM patients is a common complication of the
autoimmune disease, they may share some common immunological defects or genetic
background. There are many similarities between islet cells and neurons. Some neuronal
cell-surface markers, such as tyrosine hydroxylase for neurons, are also present on
pancreatic islets, suggesting a possible common origin o f pancreatic islet cells and neurons
(Pearse, 1982). Neurons release neurotransmitters in much the same manner as pancreatic
islets release hormone in response to stimuli. There are antigens shared between islet cells
and neurons such as gangliosides (Nayak et al, 1985) and glutamic acid decarboxylase
(GAD) (Clare-Salzler et al., 1992; Kaufman et al., 1992; Esclapez et al., 1994). Because
of these similarities between islet cells and neurons, it is thought that the immunological
process directed against islet cells could also attack neurons.

Thus, a role for the

immunopathological process in pathogenesis of diabetic neuropathy should be considered.

The humoral immunity in diabetic neuropathy
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The capacity to produce autoantibodies is an inherent property of the normal
immune system. The vast immunoglobulin repertoire gives B cells the potential to produce
autoantibodies against a list o f autoantigens.

Nevertheless, autoantibodies, including

natural autoantibodies, never appear against autoantigens in normal conditions, probably
because o f deletion or anergy o f particular autoreactive T-cell and B-cell clones early in
ontogeny.

However, the traditional theory about self-nonself being distinguished and

tolerance established in the neonatal period has been questioned recently (Pennisi, 1996).
It has been suggested that the dendritic cells and B cells of the immune system may regulate
immune activation and immune tolerance.

If B cells fail to inactivate the dendritic cells

presenting autoantigens, autoimmunity may result ( Ridge et al, 1996).
Evidence indicates that in diabetic patients with autonomic neuropathy, there are
complement-fixing

autoantibodies against autonomic

nerve

tissue

components

in

sympathetic ganglia, adrenal medulla and vagus nerve (Brown et al., 1989; Rabinowe et
al., 1990; Zanone et al., 1993.).

Anti-ganglioside G T lb IgG, associated with both

sympathetic ganglia and adrenal medulla antibodies, has been reported in IDDM patients
with neuropathy and is inversely related to the change in orthostatic blood pressure
(Rabinowe et al., 1991). In one study, sera of 120 IDDM patients were examined for the
presence of complement-fixing anti-sciatic nerve antibodies and 22% had fluorescent scores
exceeding normal control subjects (MacLaren et al., 1989).

If these antibodies attack

neuronal tissue, they should be detectable in nerve tissues as they are attacked.
Immunoglobulin deposition in the perineurial regions and axons has been noted in nerve
biopsies from diabetic patients with neuropathy (Graham et al, 1985; Schenone et al, 1988;
Milicevic et al, 1995).
Clinical evidence suggests that immune therapy is effective in diabetic neuropathy,
further supporting the notion that immune processes may be involved in the pathogenesis
of autoimmune-mediated neuropathy.

Plasmapheresis alleviates neuropathy associated

with anti-myelin IgM (Haas et al., 1988). Plasma exchange in neuropathy patients with
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IgA and IgG gammopathies, effectively attenuates neuropathy based on disability score,
muscle weakness and compound motor nerve action potentials (Dyck et al., 1991). High
dose intravenous immunoglobulin (IVIg) treatment is effective in patients with a variety of
neuropathies associated with autoimmunity, including diabetic neuropathy (Nobile et al.,
1993; Karlson et al., 1994; Krendel et al, 1995). However, the mechanism by which IVIg
acts is uncertain.
In many studies (Brown et al., 1989; Rabinowe et al., 1990; Zanone et al., 1993),
autoantibodies against autonomic nerve tissue components tend to appear more frequently
in the neuropathic patients than in the diabetic control subjects with disease of similar
duration, suggesting that neuronal tissue autoantibodies may have a role in the development
of symptomatic diabetic neuropathy.

However, it is not understood whether these

autoantibodies are primary causes (directly causing neuronal tissue damage and playing a
role in pathogenesis of neuropathy), or secondary effects of the neuropathy due to
exposure of autoantigens after neuronal tissue damage.

It is also possible that

autoantibodies raised secondarily to neuronal damage may accelerate the neuronal loss, thus
still playing an important role in the development o f neuropathy. Populations studies have
noted the presence o f complement-fixing antibody against adrenal medullary in 30% of
IDDM patients, which decrease in patients with diabetes for greater than 16 years (Brown
et al., 1989), suggesting that antibody may play an early causative role in the development
of neuropathy. Autoantibody against sympathetic ganglia is associated with a diminished
catecholamine response to changes in posture and orthostasis in IDDM patients (Brown et
al, 1989), supporting the idea that the adrenergic nervous system is a target for autoimmune
destruction.
Autoantibodies detected in sera o f patients with neurological disease have been
reported in chronic inflammatory demyelinating polyneuropathy (Weng et al., 1992),
myasthenia gravis (Rowland et al., 1991), Stiff-man syndrome (Pugliese et al., 1993;
Solimena et al., 1988: 1990), Guillain-Barre syndrome (Quarles et al., 1990), lower motor

4
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neuron disease (Freddo et al., 1986), multiple sclerosis (McFarland et al. 1989). and acute
post-infectious disseminated encephalomyelitis (Segal, 1983). Circulating antibodies may
also play a pathogenetic role in neuropathies associated with amyloidosis, myeloma,
macroglobulinemia, lymphoma, and certain leukemias (Dyck et al., 1991). It appears that
the location of the presumptive target antigen critically influences the pathogenetic potential
of autoantibodies.

Autoantibodies

directed

against cell-surface

targets

are

often

pathogenetic, such as in myasthenia gravis (characterized by autoantibodies against the
acetylcholine receptor in membranes of skeletal muscle fibers) (Schonbeck et al., 1990).
Those directed against extracellular matrix components may or may not cause damage.
Antigens may be both cytoplasmic or exposed on the cell surface, such as 64-kDa islet cell
antigen or GAD (glutamic acid decarboxylase), an enzyme involved in the synthetic
pathway of the inhibitory neurotransmitter, gamma-aminobutyric acid (Kaufman et al.,
1992).

The Cellular immunity in diabetic neuropathy
The cellular immune system is the engine of all immunity, including antibody
production. A role for cell-mediated immunity to nervous system antigens in the
pathogenesis of diabetic neuropathy has also been suggested (Segal et al., 1983; Gilbey et
al., 1988). In tissue samples from diabetic patients with severe autonomic neuropathy,
inflammatory infiltrates composed o f lymphocytes, macrophages and occasional plasma
cells are seen in autonomic ganglia and in or around autonomic nerve bundles of
unmyelinated nerve fibers (Duchen et al., 1980).

In a group of similar patients, an

increased level of circulating activated T lymphocytes was observed, suggesting a role of
the cellular immune system in the pathogenesis of neuropathy (Gilbey et al., 1988). Levels
of activated T lymphocytes are increased in newly diagnosed Type 1 diabetic patients, but
tend to return to normal within 2-3 years. Their persistence or, possibly, reappearance in
diabetic neuropathy may represent continuing immune activation against neuronal targets
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(Zanone et ai., 1993). It is unknown whether the generation o f antibody preceded this
immune infiltration.
There is evidence using the lymphocyte transformation technique, that lymphocytes
from some patients with diabetic neuropathy undergo significant stimulation when cultured
in vitro in the presence of both CNS and PNS basic protein antigen (encephalitogenic
protein and P2) (Segal et al., 1983). Cell-mediated immunity to neural antigens has also
been reported in myeloradiculitis, chronic relapsing polyneuritis (Abramsky et al., 1975)
and transverse myelopathy (Abramsky et al., 1977).

Autoantigen Identification
Identifying and characterizing the relevant autoantigens is still a challenge in
destructive organ-specific autoimmunity, but it might lead to advances in diagnosis,
treatment and even prevention of autoimmune diseases.
Data from studies of animal diabetes and autoantibodies in IDDM suggest that
many epitopes or antigen structures become autoantigens during disease pathogenesis.
Previous studies on antibodies to autonomic nervous structures indicated a higher
prevalence o f these antibodies in recent-onset Type 1 diabetic patients, who were ICA (islet
cell cytoplasmic antigen) positive, than in those with long-term diabetes. This suggests that
antibodies to nerve tissue and ICA may have target antigens in common (Brown et al.,
1989).

However, in other studies no significant correlation between anti-nerve tissue

autoantibodies and ICA or other conventional tissue autoantibodies was found. Therefore,
antibodies to nerve tissue may occur independently and the target antigens are tissue
specific (Zanone et al., 1993).

a. Gangliosides
Studies suggest that the autoantigens of pancreatic tissues have the properties o f a
glycolipid containing sialic acid (Nayak et al., 1985; Powers et al., 1984; Dotta et al.,
1989).

This may account for the failure to detect islet-cell surface antibodies with

4
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Monoclonal anti-ganglioside

antibodies produced by immunization with fetal rat brain react specifically with all cell
surfaces of pancreatic islets o f human, rat, mouse (Ariga et al., 1987).

It is generally

thought that in organ-specific autoimmune diseases, the autoantibodies are specific for each
organ and do not cross-react (Bottazzo et al., 1986).

However, some islet cell antigens

(e.g., gangliosides) are present in significant amounts in other organs besides pancreatic
islets, such as neurons, renal glomerular cells, retinal microvascular pericytes and adrenal
medulla. Thus, it is possible that the common antigens may be involved in multiple organ
damage and may cause diabetic complication, such as neuropathy, retinopathy and
nephropathy (Nayak, et al., 1985; Eisenbarth et al., 1988).
Anti-ganglioside antibodies have been found in Guillain-Barre syndrome (Quarles
et al., 1990; Ilyas, 1988), lower motor neuron disease (Freddo et al., 1986;), chronic
inflammatory polyneuropathy (Baba, 1989), multiple sclerosis (Endo et al., 1984), and
amyotrophic lateral sclerosis (Pestronk, 1988b), neuromuscular disease (Adama et al.,
1991), as well as neuropathy in type I diabetes (Rabinowe et al., 1991).

Indeed,

ganglioside GM1 treatment with formation of anti-ganglioside antibodies is associated with
an increased incidence o f Guillain-Barre syndrome (Landi et al., 1993), suggesting a
causative relationship for GM1 autoantibodies.
In neuroblastoma cells, gangliosides are abundant on cell surface membranes (W u,
1991). The composition o f gangliosides in different cell types or cell lines varies.

IgM

antibody that recognizes gangliosides GM1, G D lb and asialo-GM l is reported in motor
neuron diseases such as lower motor neuron disease, multifocal motor neuropathy and
acute axonal neuropathies (Latov et al., 1988; Geisler et al., 1991). Anti-ganglioside G T lb
IgG, associated with both sympathetic ganglia and adrenal medulla antibodies, is reported
in IDDM patients with autonomic neuropathy (Rabinowe et al., 1991). Thus, ganglioside
should be considered as an important candidate antigen in autoimmune-mediated diabetic
neuropathy.

'd
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b. Myelin Basic Protein
Anti-myelin basic protein antibodies are reported in Guillain-Barre syndrome,
multiple sclerosis and experimental allergic neuritis (EAN) induced in Lewis rats.
Administration

of

myelin

basic

protein

suppresses

experimental

autoimmune

encephalomyelitis by neutralizing antibody (Khoury et al., 1990). Considerable evidence
favors a role of anti-myelin antibody in mediating demyelinating polyneuropathy (Hays et
al., 1987; Hafler et al., 1986; Steck et al., 1983). It remains to be determined whether anti
myelin antibody plays a role in diabetic neuropathy.

c. Glutamic acid decarboxylase (GAO)
GAD is an enzyme involved in the synthesis of the neurotransmitter gamma aminobutyric acid (GABA). Antibody against GAD is present in sera o f patients with type 1
diabetes and GAD is considered to be an autoantigen in pancreatic islets (Clare-Salzler et
al., 1992). GAD exists in two isoforms, 65kDa and 67kDa, that differ in their
intraneuronal distributions (Kaufman et al, 1992). GAD67 is widely present in cell bodies,
whereas GAD65 is prominent in many axon terminals (Esclapez, 1994).
GAD65 are

GAD67 and

different gene products, with GAD67 the predominant form in neurons

(Kaufman et al, 1992). Higher titers of anti-GAD antibodies have been reported in a small
number of diabetic patients with autonomic neuropathy (Kaufman, 1992). O f interest, antiGAD antibodies appear to cause the neurological disorder in Stiff-Man Syndrome, which is
often accompanied by diabetes (Karlson et al., 1994).

Because GAD antibodies may be

involved in different diseases, the epitope on GAD recognized by antibodies may be critical
to the physiological and disease-specific effects (Daw et al., 1996).
antibody may play a role in diabetic neuropathy.
this may not be the case.

Thus, anti-GAD

However, several recent studies argue

Anti-GAD65 antibodies are present in a high proportion of

patients with diabetic neuropathy, but are not exclusively associated with it.

High

prevalence of autoantibodies to GAD in long-standing IDDM is not a marker of
symptomatic autonomic neuropathy (Zanone et al., 1994; Vinik et al., 1995). There is no

•d
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correlation between the presence o f anti-GAD65 antibodies and the presence of
autoantibodies to sympathetic ganglia, vagus nerve, or adrenal medulla structures identified
by immunofluorescence.

Nor are GAD-antibodies associated with disturbed autonomic

nerve function (Sundkvist et al., 1994).

Moreover, GAD is a cytoplasmic enzyme and

access of the autoantibody to the protein is problematic.

Thus, the role of anti-GAD

antibodies in diabetic neuropathy remains elusive.

d. Nerve growth factor (NGF) and NGF receptor
Shared sequence homology between portions o f the nerve growth factor (NGF) and
pro-insulin molecules suggests an autoimmune mechanism acting through effects of anti
insulin antibodies modifying NGF activity (Schmidt, 1993). Anti-insulin antibodies are
common in IDDM patients and cross-reaction with NGF could lead to the immunologicallymediated destruction of nerve tissues that are depend on NGF.

NGF stimulates and

maintains growth and differentiation o f sensory and sympathetic nerves and dorsal root
ganglion cells during early development. NGF is also necessary for neuronal survival,
morphology and function in maturity. NGF receptor TrkA knockout mice show deficient
C-fiber function and lack sympathetic nerve development. An immune attack on NGF
might result in damage to autonomic nerves, leading to neuropathy.

Autoantibodies to

NGF have been reported in the sera of patients with autoimmune diseases and diabetes
(Dicou et al., 1993; Faradji et al., 1990).

However, a recent investigation found no

significant difference in anti-NGF antibody level among groups of diabetic patients with
neuropathy, diabetic control patients and normal control subjects (Zanone et al., 1994).
Any relationship between NGF and autoimmunity remains to be determined.

e. Other membrane lipids/protein components
Membrane lipids, such as phospholipids have been thought to be important in
diabetic neuropathy (Greene et al., 1989; McNeil et al., 1991; Vinik et al., 1995).
Membrane proteins, such as the voltage-dependent L-type calcium channel, have been
suggested as autoimmune targets in the neurodegenerative diseases Lambert-Eaton
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The

frequency o f anti-phospholipid antibody is significantly higher in diabetic neuropathy
patients than in the general population or patients without neuropathy according to a recent
study (Vinik et al., 1995). Anti-cardiolipin antibodies occur in autoimmune disease and a
phospholipid-beta 2-glycoprotein I complex has been suggested to be the antigen (Hunt et
al., 1992).

A significance o f anti-phospholipid and anti-cardiolipin antibodies in the

pathogenesis o f diabetic neuropathy has not been established.

1.3.

Cellular mechanism of neuronal death
Recent studies indicate dysfunctional control of programmed cell death (apoptosis)

is involved in the development of autoimmune diseases and neurodegenerative diseases
(Thompson., 1995; Carson et al., 1993). One mechanism underlying autoimmunity is the
defective ability of the immune system to delete self-reactive T and B lymphocytes by
apoptosis, which could predispose to autoimmune disease.

Some studies

have

demonstrated that apoptosis may also play a role in the pathogenesis of IDDM. It has been
reported that IgM in sera from IDDM patients causes an increase in voltage-dependent Ltype calcium channel activity of insulin-producing cells. The subsequent increase in the
concentration o f free cytoplasmic Ca2+ was associated with DNA fragmentation and
apoptotic cell death (Berggren et al., 1993). More recently, genetic analysis o f non-obese
diabetic (NOD) mice showed that the apoptosis related gene bcI-2 mapped close to the
gene region which is associated with periinsulitis. The bcl-2 NOD (non-obese diabetic)
mouse haplotype is linked to an elevated serum IgG. Activated T lymphocytes from NOD
mice also showed a marked resistance to induction o f apoptosis (Garchon et al., 1994).
However, little is known about the relevance of apoptosis and the regulation of apoptosis
to neuropathic complications in IDDM patients.
Apoptosis occurs through the activation of a cell-intrinsic program.

The basic

machinery to carry out apoptosis appears to be present in essentially all mammalian cells,
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Neurons also have a programmed cell death pathway.

Approximately half of the neurons produced during embryogenesis normally die before
adulthood.

Apoptotic morphological changes and DNA fragmentation have been

described in 3-day-old cultured cortical neurons exposed to glutamate (Kure et al., 1991).
Target-derived neurotrophic factors are known to be major determinants o f programmed
neuronal cell death (Garcia et al, 1992). Sympathetic neurons undergo RNA-and protein
synthesis-dependent programmed cell death when deprived o f nerve grow th factor
(Deckwerth et al, 1993). In diabetic neuropathy, the most important pathological change
is loss of myelinated and unmyelinated axons (Chopra et al, 1971; Brewster et al, 1994).
This is similar to a wide variety of neurological diseases, such as Alzheimer’s disease,
Parkinson’s disease, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy, and
various forms of cerebellar degeneration, which are characterized by the gradual loss of
specific sets of neurons but without an obvious inflammatory reaction. In these diseases,
apoptosis has been suggested to be the mechanism of neuronal cell death (Thompson,
1995).
Apoptosis is characterized by condensation o f cytoplasm,

compacting of

chromatin, formation of a convoluted plasma membrane and extensive fragmentation of
chromosomal DNA into oligomers. The DNA ladder that forms during apoptosis results
from the activation of an endogenous endonuclease. An increase of cytosolic calcium at an
early phase of apoptosis may contribute to the activation of the endonuclease (Joseph et al,
1993). Meanwhile, there is no tissue inflammation. The suicide program is regulated by
many extrinsic and intrinsic signals, and the threshold of apoptotic cell death is also
dynamically regulated by multiple inducers and inhibitors of gene products (Steller, 1995).
Removal of trophic factors, excessive exposure to excitatory amino acid neurotransmitters,
oxidative stress, calcium toxicity and mitochondrial defects have all been postulated to
contribute to the pathogenesis of apoptotic neuronal death.
Several apoptosis-related oncogene products are expressed and regulated in

•i
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neurons. Bcl-2, a cell death suppressor, is found in the mitochondrial membrane, the
nucleus and the endoplasmic reticulum. A high level of expression o f bcl-2 in sympathetic
neurons prevents cell death induced by deprivation of nerve growth factor (Garcia et al,
1992).
A nother important regulator of neuronal apoptosis is the low-affinity N GF receptor,
p75, which appears to be important for neuronal cell death and survival (Rabizadeh et al.,
1993). p75 has been shown to increase the affinity o f TrkA for NGF and to enhance the
specificity o f the Trk family of receptors for neurotrophins (Barbara et al., 1991).

It is

now apparent that p75 is yet another cellular death signaling protein (Finkel, 1996). p75
has some sequence similarity to the tumor necrosis factor receptors (TNFR-I and TNFRII), the human cell surface antigen Fas (APO-1), and the B cell antigen CD40, all of which
mediate cell death through an intracellular "death domain" (Bazzoni, 1996).

Because of

structural and functional homology between the NGFR/TNFR system, the hypothesis that
p75 serves as a constitutive cell death-promoting molecule that is inhibited by NGF binding
was put forward (Finkel, 1996).

Evidence suggested that because p75 enhanced the

survival o f neurons from developing embryos, it might act as a death gene for older
neurons. The type of cell death induced by p75 was apoptosis and neural cell survival was
enhanced by binding of NGF to p75 (Rabizadeh et al., 1993). Recent studies have further
supported the concept of p75 as a constitutive regulator of apoptosis and suggested that
inhibiting p75 expression with antisense oligonucleotides can rescue neurons from death
(Finkel, 1996).
Fas/APO-1 (APO-1, CD95), another member of the NGFR/TNFR family, is a
type I cell-surface receptor with a molecular weight o f 35-40kDa. Binding o f the receptor
by ligand or antibody initiates cell death (Bazzoni, 1996).

Fas-mediated apoptosis

triggered by ligation of Fas molecule seems to be target dependent.

For example,

macrophages express Fas and undergo apoptosis when cultured with anti-Fas. In contrast,
although endothelial cells can express the Fas molecule, Fas ligation is insufficient to

*
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function among cells

(Richardson et al., 1994). The susceptibility o f Fas-bearing cells to Fas/APO-1 antibodymediated cell killing is also modulated by cytokines.

Fas dependent cytotoxicity were

augmented by pre-exposure to interferon gamma and TNF alpha in maligment glioma cells
(Weller eta l, 1994).
Fas/APO-1 antigen was originally described in fibroblasts, some malignant
tumor cell lines (Yonehara, 1989) and some cells o f lymphocyte lineage (Nagata, 1995).
Subsequently, a variety of normal cells have been found to express this cell surface
glycoprotein. In mice, the mRNA coding for Fas antigen is present in the thymus, heart,
liver and ovaries (Watanabe-Fukunaga et al., 1992).

In human tissue, Fas/APO-1 is

expressed by epithelial cells, satellite cells o f the autonomic ganglia and some
mesenchymal cells, such as fibroblasts and endothelial cells. Histiocytes and subsets of
T- and B-Iymphocytes, as well as a number of malignant cells, also express the Fas/APO1 antigen (Owen-Schaub et al., 1993). However, Fas expression has not been reported in
neurons, although Fas antigen was found in brains o f patients with Alzheimer-type
dementia, mainly expressed by a subset of reactive astrocytes.

These astrocytes may

undergo the Fas-mediated apoptotic process (Nishimura et al., 1995).
The role o f Fas and Fas ligand in regulation o f cytotoxic T lymphocytes,
especially in the pathogenesis of autoimmune diseases, has been noted (Hanabuchi et al.,
1994). For example, point mutation in the Fas cytoplasmic domain and Fas ligand in
homozygous mice caused conditions termed Ipr (lymphoproliferation) or gld (generalized
lymphoproliferative disease), which are similar to systemic lupus erythematosus, a human
autoimmune disease with neurological complications (Nagata, 1995).
Many cell cycle-regulating genes, including several cyclins, c-fos, c-myc, c-jun,
cdc-2, RB and p53 have been suggested as mediators of cell survival, division or
apoptotic death (Pandey et al., 1995).

p53, the protein product o f a tumor suppresser

gene, and inhibitor o f cell mitosis, acts as a direct effector causing apoptosis.
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Overproduction of normal p53 protein in a myeloid leukemia cell line induces rapid
apoptotic cell death (Yonish-Rouach et al, 1991). What their role in neuronal cell death is
remains to be explored.

1.5.

Rationale
Diabetic neuropathy is a life-threatening complication in a significant proportion of

patients with all forms of diabetes mellitus, whose etiology is unclear. Studies indicate the
appearance of autoantibodies before clinical presentation, thus, progressive target cell
destruction may develop over several years (Boitard, 1992).

On these bases, it may be

possible to identify individuals at high risk for development o f EDDM and its neuropathic
complications using specific genetic and immunological assays. This raises the possibility
that effective immunotherapies could be developed to prevent the target cell destruction,
while the individual still has substantial target cell reserves. The presence of autoantibodies
to antigens contained in islet cells has become a reliable means of predicting future
development of IDDM, although islet cell antibodies are heterogeneous and some antibodies
may be more predictive than others (Eisenbarth et al., 1988). As mentioned before,
autoantibodies against neuronal tissue may not be correlated with ICA (islet cell cytoplasmic
antigen) antibodies. A method to predict diabetic neuropathy by measurement of antibodies
to specific neuronal autoantigens may provide a means to earlier identification of people at
risk for developing neuropathy and allow for development of strategies for prevention.
In these studies, we used an adrenergic clone o f a murine neuroblastoma tumor,
N1E-115 (NB) as an autonomic neuron model to investigate the humoral factors in sera of
diabetic

patients

with

neuropathy

on

neuronal

cell growth

and

differentiation.

Neuroblastoma is a neoplasm o f the adrenal medulla and components of the peripheral
autonomic nervous system.

They are widely used as a model for neuronal research,

because they exhibit properties similar to differentiated sympathetic neurons such as neurite
outgrowth, synthesis of neuropeptides or neurotransmitters and expression of receptors for

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Chapter I . Background and Significance

17

pharmacological agents (Sonnenfeld, 1982). Such a neuronal cell model might allow early
prediction and prevention of diabetic neuropathy. It could also be a useful model to study
the mechanism of neuronal death, autoimmune pathogenesis and possible immunotherapy as
well as the protective effects o f neurotrophic factors or other new drugs on diabetic
neuropathy.

i
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CHAPTER II. THE HUMORAL EFFECT OF DIABETIC PATIENTS’ SERA
ON NIE-II5 CELL PROLIFERATION AND DIFFERENTIATION

Previous evidence showing that autoantibodies

to autonomic nerve

tissue

components had a higher frequency in neuropathic patients with diabetes than in diabetic
control subjects with disease

o f similar duration indicated that neuronal

tissue

autoantibodies have a role in the development o f symptomatic autonomic neuropathy
(Brown et al., 1989). However, it was unclear whether these autoantibodies can directly
cause neuronal tissue damage or whether they were only a secondary manifestation,
because of the exposure of autoantigen after neuronal tissue damage. Also, what was the
possible mechanism by which these antibodies or other humoral factors besides
immunoglobulins could cause neuronal death? To answer these questions, the humoral
effect o f diabetic patient sera (IDDM, NIDDM) and control subject sera on N IE -115
neuroblastoma cell growth and differentiation was investigated.

2.1. Diabetic patients' sera collection and N1E-115 neuroblastoma ceil line
as a model of sympathetic neurons
Serum was collected from patients in three categories: control subjects,

patients

with insulin-dependent diabetes mellitus (IDDM) and patients with non-insulin-dependent
diabetes mellitus (NIDDM) (Table. 1).

Patients with IDDM, or type I diabetes, were

separated into groups with neuropathy and without neuropathy. Diabetic neuropathy was
established by the presence o f symptoms, signs, and quantitative electrophysiology,
electromyography or other neuropathy tests, according to the recommendation o f the
American Diabetes Association and the American Academy o f Neurology (1988).
The sex distribution between groups was well matched. Because of the nature o f
the

disorders,

patients

with

NIDDM

were

significantly

heavier
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and

older

Table 1. Sera were collected from healthy controls and patients with either NIDDM or
IDDM. IDDM patients were further separated into groups with neuropathy or without
neuropathy. The serum glucose level, H b A lc level, duration o f diabetes as well as
cholesterol and lipid levels were determ ined by group. The age and weight o f NIDDM
patients was significantly higher (*, p<0.05) than any o f the groups. The serum glucose
and H bA lc measures were elevated in the diabetic groups compared to controls.
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Parameter
Neuropathy
Sex
Age (yr)
Weight (kg)
Glucose (mg/dl)
Cholesterol (mg/dl)
Triglycerides (mg/dl)
HDL-C (mg/dl)
LDL-C (mg/dl)
HbA ic(%)
Duration o f Disease (yr)

Control
0 /1 1
7F/4M
41.2*2.6
68.1*6.1
8 9 .4 * 1 .3
222.4*18.3
97.3*15.4
6 1.2*4.9
141.7*17.4
Range [3.4-6.1 ]
NA

Type 1 diabetes
9/9
6F/3M
36.6*3.1
70.7*4.9
226*37.6
220*18.3
100*14.0
64*4.0
144*22.2
9 .2 * 0 .6
19.7*2.86

Type 1 diabetes
0/7
3F/4M
37.6*3.1
78.1*3.1
128*29.3
221*19.3
87*11.3
59*2.5
145*18.4
7.2*0.3
15.3*3.4

____________
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Type 2 diabetes
9/10
6F/4M
62.1*3.7*
87.7*5.2*
217*22.0*
230*19.3
183*32.4
50*4.9
147*17.1
8.5*0.7
10.4*2.4
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Serum glucose level and H bA lc in both EDDM and NIDDM

patients were significantly higher than the normal range.

The duration o f diabetes was

slightly longer in both IDDM groups than the NIDDM patients, but did not reach statistical
significance.

Cholesterol and lipid levels did not differ between groups.

None o f the

subjects had clinical nephropathy. Serum urea and creatinine measurements were normal.
The N1E-115 neuroblastoma cell line was an adrenergic cell clone derived from the
C1300 murine neuroblastoma tumor (Amano, 1972).

This cell line had the capacity to

develop the characteristics of adrenergic neurons when maintained in cell culture, and
therefore was representative of sympathetic autonomic neurons.

These cells could be

induced to differentiate and extend neurites by removal of serum from the media.

2.2. The humoral effect of diabetic patients' sera (IDDM, NIDDM) and
control sera on neuronal cell proliferation
Neuronal cell growth tests were performed by growing flasks of N1E-115 cells to
confluence, lifting the cells with Pucks' D1 solution, and subculturing at 105 cells per
35mm2 dish. The cultures were split into four groups (IDDM, NIDDM, control and FBS)
of four plates each, cultured in DMEM (4,500mg/L D-glucose) supplemented with 10%
human serum from each group. Each day for 4 consecutive days the cells from one plate in
each group were lifted and the number of viable cells in each dish was determined using
trypan blue exclusion criteria. The viable cell counts were taken over a 5-day period
(including the day o f plating), and the growth curves for each group were established.
Figure 1 shows the mean viable cell number in cultures treated with sera from 5
groups during Five days culture period.

Control group included 9 individuals; IDDM

without neuropathy included 7 individuals; IDDM with neuropathy included 6 individuals;
NIDDM included 10 individuals and 9 with neuropathy. The results show that N IE -115
neuroblastoma cells grow rapidly in regular 10% FBS-containing DMEM media (F ig .l;
Fig.2-a). The viable cell numbers were reduced when cells were grown in media containing

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

F igure 1. Mean growth curves for N1E-115 NB cells in DMEM media with 10% serum
from different population groups. The N1E-115 cell cultures were exposed to 10% fetal
bovine serum (FBS) or control sera, sera from IDDM patients w ith and w ithout
neuropathy or NIDDM patients' sera with neuropathy for 5 days, the viable cells were
counted by trypan blue exclusion criteria and expressed as mean±SEM. Cell growth was
significantly inhibited (*p< 0.05) by sera from IDDM patients with neuropathy compared
to cells grown in sera from control, NIDDM, and IDDM patients without neuropathy on
days 4-5 o f culture. Viable cell num ber was determined using trypan blue exclusion
criteria. The control group included 9 individuals; IDDM without neuropathy included 7
individuals; IDDM with neuropathy included 6 individuals; NIDDM included 10
individuals. Statistical analysis was perform ed by analysis of variance and W ilcoxon
rank sum test.
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Figure 2. Representative photomicrographs o f N1E-115 NB cell grow th in DMEM
media with 10% serum from different groups: (A). 10% FBS; (B). 10% serum from a
control subject; (C). 10% serum from an IDDM patient with neuropathy; (D). 10% serum
from an NIDDM patient with neuropathy. N1E-115 cells in A, B and D showed the
normal cell appearance and most cells were health, while those treated with IDDM serum
showed cytotoxic effects indicated by cell shrinkage, lifting from attachment and cell
death (C).
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10% human serum. There was no statistically significant difference between the healthy
control group, NIDDM with neuropathy and IDDM without neuropathy.

In contrast,

viable cell numbers in cultures treated w ith serum from the IDDM patients with neuropathy
were significantly lower than in the FBS cultures by day 2 (p<0.05) and cultures with
NIDDM and IDDM serum without neuropathy by day 4 and 5 (p<0.05).

In 3 o f the 6

cases, IDDM serum associated with neuropathy appeared to cause total cell death within 3
days. However, this also occurred in response to one serum sample from a IDDM patient
without neuropathy.

2.3. The humoral effect of diabetic patients'sera (IDDM,NIDDM) and
control sera on neuronal cell differentiation
N IE -115 cells were subcultured into 12-well culture plates for 2 days in DMEM
media supplem ented with 10% FBS. The cultures were then exposed to individual serum
from each group used in the cell growth studies for 24 hr. The serum w as then removed
from the culture media and the cells grow n in serum-free DMEM for another 24 hr to
induce differentiation. The differentiated cell was defined as one that had at least one
neurite extended from the cell body by more than one cell diameter. Two hundred cells
from each well were evaluated under phase contrast microscopy and the differentiation rate
(%) and length o f neurites were determined.
The results of the study show that the sera from the IDDM patients w ith neuropathy
group significantly (p<0.05) inhibited neuroblastoma

celldifferentiation after 24 hr

(differentiation rate = 18.7%) compared to NIDDM (30.0%) and control (42.4% ) groups
(Fig. 3, Fig. 4). However, once the cells were induced to differentiate, the neurite length
extended did not show a significant difference after exposure to serum from the different
groups (Fig. 5.).

2.4. The Effect of IDDM sera pre-absorbed by N1E-II5 cells and mouse
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liver acetone powder on cell proliferation.
To determine whether the inhibition of cell proliferation was due to the presence of
a cytotoxic factor in the serum, or the absence of a supporting factor required for cell
survival, human sera from 3 subject groups were pre-absorbed by N IE -115 neuroblastoma
cells (Fig. 6) and mouse liver acetone powder. Aliquots of sera were pre-incubated with
106 neuroblastoma cells or 1 mg of mouse liver acetone powder at 37°C for 20 min. After
centrifugation for 10 min at 3000xg, the supernatant sera were applied to neuroblastoma
cell cultures as a 10% concentration in DMEM for 24 hr and compared with cell cultures in
10% non-absorbed serum media.

The growth inhibition o f IDDM serum was totally

reversed by pre-absorption to neuroblastoma cells but not mouse liver acetone powder preabsorption.

The results demonstrated that cell growth inhibition was caused by some

'cytotoxic factor' in IDDM serum that could be pre-absorbed by neuroblastoma cells but
not other mouse tissue extracts prepared with organic solvents. It also indicates that the cell
growth inhibition or death was not only caused by a deficiency o f required factors in EDDM
serum (Fig. 7).

Summary
Using N1E-115 neuroblastoma (NB) cells as an adrenergic neuronal model, we
found that the serum from EDDM patients with neuropathy had greater effects and more
frequently inhibited neuronal cell growth and differentiation than control sera and sera from
non-neuropathic IDDM. In some cases, individual IDDM sera caused neuronal death. This
inhibiting or neurotoxic effect of IDDM serum could be partially reversed by NB cell preabsorption, which suggested that the cytotoxic effect was caused by a cytotoxic factor in
the serum, although we have not excluded that neurotrophic factors in the serum may also
have some effect. This cytotoxic effect could not be removed by preabsorption with mouse
liver powder prepared with an organic solvent, indicating that it could be a tissue specific
effect or that the antigen was extracted by organic solvents.
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Figure 3. N1E-115 NB cell differentiation rate after exposure to individual serum from
different groups. N 1E-115 neuroblastom a cells were exposed to 10% serum from
different population groups for 24 hr and then induced to differentiate by removing serum
from the medium for 24 hr. The cells extending neurites were counted, expressed as a
percent o f total cells and compared among different groups. There was a significant
inhibition (*p<0.05) in the percentage o f cells extending neurites in response to IDDM
serum, but not in response to NIDDM serum. There were 9 individuals in control group,
10 individuals in IDDM group and 10 individuals in NIDDM group tested.
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Figure 4. Representative photomicrographs o f m orphology o f differentiated NB cells
after treatment w ith different serum groups. N1E-115 neuroblastoma cells treated with
10% serum from different population groups for 48 hr and then cultured in serum-free
medium to induce differentiation: (A) Control; (B) IDDM; (C) NIDDM. Serum from an
IDDM patient with neuropathy (B) inhibited neurite extension.
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F ig u re 5. the neurite length after exposure to sera from different groups. N1E-115
neuroblastom a cells were cultured in D M E M m edia containing 10% serum from
individuals of different population groups for 48 hr and then cultured in serum free media
to induce neurite extension (differentiation). The length o f the longest neurite on each
evaluated cell w as measured under m icroscopy. At least 20 differentiated cells were
measured from each individual. There w ere 9 individuals in control group, 10 individuals
in ID D M group and 10 individuals in N ID D M group evaluated. The results show that
there w as no significant difference am ong different groups.
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F igure 6. The principle of immune pre-absorption. For pre-absorption studies, 1()6NB cells were collected and
incubated with IDDM serum, which had shown a cytotoxic effect on NB cell, at 37°C for 30 min. The cells were
precipitated, and the supernatant serum was added to the NB cell culture to examine the effect on cell growth and
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compare with serum before absorption. The absorbed NB cells were lysed and the protein components were collected
and separated by SDS polyacrylamide gel electrophoresis to examine whether extra proteins were absorbed onto the
cells.
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Figure 7. Photomicrographs of the effect o f IDDM sera pre-absorbed by NB cells on cell
growth. N1E-115 neuroblastom a cell cultures exposed to serum from a patient with
IDDM before or after pre-absorption by neuroblastom a cells, (a) The IDDM patient
serum inhibited NB cell growth and caused cell death, (b) The same IDDM patient serum
absorbed by NB cells showed a complete reversal of the cytotoxic effect. These studies
demonstrated the presence of a cytotoxic factor in the IDDM serum.
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CHAPTER III.

IDENTIFY THE NEURONAL TOXIC FACTORS IN THE

SERA OF IDDM PATIENTS WITH NEUROPATHY

In the previous studies, we found that there was a cytotoxic factor in IDDM patients
with neuropathy, but not in sera from the NIDDM group and control group. Because there
was a different effect of IDDM and NIDDM sera on proliferation and differentiation, this
suggested a difference in pathogenesis o f neuropathy between IDDM and NIDDM groups.
Based on this and previous studies by other investigators, an autoimmune-related humoral
factor, such as autoantibodies, was considered in mediating the neuronal death effect of
IDDM sera.

Here, we investigated whether this cytotoxic effect was mediated by an

immunoglobulin and/or other humoral factors.

3.1. Effect o f IDDM sera pre-absorbed by protein A on cell growth.
Affi-Gel protein A agarose (Bio-Rad, Inc., Richmond, CA) was washed with PBS
and added to the test serum at a 2:1 (v/v) dilution. After incubation for 30 min in a 37°C
water bath, the mix was centrifuged at 10,000xg for 30 min to precipitate the protein A gel.
Identical untreated sera were tested in parallel with the protein A precipitated sera for both
control and IDDM groups. The groups tested included 6 IDDM patients with neuropathy
or 6 control subjects. The results showed that precipitation o f immunoglobulin (Ig) from
control sera had little effect on cell growth (8.6±1.3

x 103 cells before precipitation and

9.4±1.8 x 105 cells after Ig precipitation). In contrast, depletion of Ig from IDDM serum
significantly (p<0.05, one way ANOVA) improved cell growth (3.7±1.5 x 103 cells before
precipitation and 8.0±1.2 xlO5 cells after precipitation), There was an 3/4 recovery from
57% inhibition before protein A treatment to 15.2% inhibition after protein A treatment,
indicating that the protein A-agarose was able to remove about 75% of the cytotoxic effect
in IDDM serum (Fig. 8).
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Figure 8. The effect o f protein A precipitated sera on N1E-115 cell growth. Sera were
precipitated with protein A from 6 IDDM and 6 control subjects. Equal numbers o f N1E115 cells were cultured in DM EM media supplemented with 10% o f one of four test sera:
control serum, IDDM serum, protein A-absorbed control serum or protein A-absorbed
IDDM serum. After 72 hr the viable cells were counted and the mean for each group was
determined. There w as a significant reduction (*p<0.05) in cell number in cultures
treated with IDDM sera compared to cultures treated w ith control sera. However, after
protein A absorption, IDDM sera were able to support cell growth similarly to untreated
control sera. There w as a 73.3% recovery from inhibition before protein A treatment,
indicating that the protein A-agarose was able to remove the cytotoxic factor in IDDM
serum in large portion. There was no significant change in the ability of control sera to
support cell growth after protein A absorption.
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3.2.

Effects of immunoglobulin

fractions extracted from diabetic sera

(IDDM, NIDDM) and control sera on cell growth.
Immunoglobulin was precipitated from sera of 10 subjects from each of the IDDM,
NIDDM and control groups.

Immunoglobulin was precipitated from the test sera by

gradually adding saturated ( N H ^ S C ^ to the serum to a final concentration of 40%, and
the slurry was stirred at 4°C overnight. The solution was centrifuged at 10,000xg for 30
min. The supernatant was removed and the pellet was resuspended in pH 7.4 PBS and
dialyzed with 3 changes of 10 volumes o f PBS to remove (N H 4) ,S 0 4. Immunoglobulin
fractions isolated from serum from each subject were tested separately in neuroblastoma
cell cultures, at a concentration o f 10% serum equivalents in DMEM plus 10% pooled
human serum (Gibco, Grand Island, NY).

Viable cells were counted for 5 consecutive

days to determine the effect o f the Ig fractions on cell growth. W hen the immunoglobulins
precipitated were applied to the cell culture media in the absence o f serum, the cells did not
grow well because of the lack o f serum and began differentiating. However, when the Ig
isolated from IDDM serum was added to medium containing 10% o f commercial pooled
human serum (Gibco, Grand Island, NY), cell growth w as significantly (one way
ANOVA, p< 0.01) inhibited by day 4 and 5 of culture, compared to the growth in the
presence of Ig precipitated from control serum (Fig. 9). The growth o f cells in media with
Ig from the control group sera did not differ from that of media containing 10% pooled
serum alone (Fig. 9).

3.3. Effects of heat inactivated IDDM and control sera on cell growth.
Test sera from IDDM and the healthy control groups were heated in a 56°C water
bath for 30 min to inactivate the complement to test the effect on neuroblastoma cell
growth. Heat inactivated serum was then added to the DMEM media and incubated for 72
hr as described before. Non-heated serum was tested in parallel w ith the heated
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F igure 9. The effects of immunoglobulin fractions extracted from different groups on
N1E-115 cell grow th. The effect of im m unoglobulin-containing fractions precipitated
from serum o f 10 subjects in each of the IDDM , NIDDM and control groups on NB cell
growth, expressed as mean±SEM . Cells w ere grown in DMEM media supplem ented
with 10% of a pooled normal human serum . Immunoglobulin isolated from sera in the
test groups were added to cell cultures for 5 days. The viable cell number was counted by
trypan blue exclusion criteria.

There w as a significant (*p<0.05) reduction in cell

numbers in cultures treated with Ig isolated from IDDM sera by day 5 compared with
control and NIDDM groups.
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Figure 10. Effects o f IDDM and control sera treated by heat inactivqation on N1E-115
cell growth.

Equal num bers of N1E-115 NB cells w ere cultured in DMEM media

supplemented w ith 10% o f test sera from 4 different groups: 6 control sera, 6 IDDM sera,
and the same sera heat inactivated (56°C for 30 min). A fter 72hr culture the viable cells
were counted. The cytotoxic effect o f IDDM sera w as reversed by heat inactivation.
There was a 66.2% recovery from cytotoxicity (48.5% inhibition before heat treatment
and 16.4% inhibition after heat treatment). Paired t-test showed statistical significance
(p< 0.05). There was no significant difference before and after heat treatment in the
control group.
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counterparts in all studies. The results indicated that heat treatment o f control serum had
little effect on cell grow th compared to that o f untreated serum.

In contrast, for IDDM

serum that had cytotoxic effects on cell proliferation, heat inactivation significantly
(p<0.05, paired t-test) reversed the inhibiting effect on the cells in all cases (Fig. 10), with
a 2/3 recovery of the cytotoxic serum effect (48.5% inhibition before heat treatment and
16.4% inhibition after heat treatment).

3.4. Identification o f the factor in IDDM serum against N1E-115 cells by
immunocytochemistry
A number of autoantigens have been proposed as candidates for the targeting of
autoimmune immunoglobulin in diabetic neuropathy, including glutamic acid decarboxylase
(GAD), gangliosides and phospholipids. Because GAD is cytoplasmic in neuronal cells
and gangliosides and phospholipids are membrane components, we felt that identification
of the topography of the antigens recognized would be helpful. The IDDM and control sera
were tested for binding to the surface or cytoplasm o f the neuroblastoma cells by
immunocytochemistry. Anti-GAD antibodies, including anti-carboxy terminal of GAD-65,
anti-amino terminal of GAD-65 and anti-GAD 67, all were provided by Dr. Ake Lemmark
(Karolinska Institutes, Stockholm , Sweden). Neuroblastoma cells were plated at I04 cells
in 35mm2 tissue culture dishes on sterile coverslips and grown for 2 days. The cells were
fixed in 4% paraformaldehyde in PBS for 60 min, blocked by 10% normal goat serum in
PBS for 30 min, incubated with a 1:100 dilution of test human serum for 90 min, and
finally exposed to a fluorescein isothiocyanate (FITC)-labeled goat anti-human IgG
secondary antibody (Sigma Chemical Co.,

St. Louis,

MO) for 60 min.

After

immunostaining, the cells were mounted on slides using o-phenylenediamine (lm g x m f^ )
in 90% glycerol and examined by fluorescence microscopy.

To examine cytoplasmic

immunostaining, the cells were permeabilized after fixation by immersion in acetone for 7
min prior to the addition o f 10% goat serum.
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Figure 11. Indirect immunofluorescence show ing the IgG binding pattern od IDDM
serum on N1E-115 cells (1). Indirect immunofluorecence (IF) was perform ed on N1E115 cells using individual serum from different groups as primary antibody and FITCIabeled anti-human IgG as secondary antibody. (A) Representative photomicrograph of
IF with IDDM serum which induced cell death as primary antibody on N1E-115 cells
fixed on cover slide. (B) Representative photomicrograph o f IF with IDDM serum as
primary antibody on differentiated cells. (C) Representative photomicrograph o f IF with
NIDDM serum as the primary antibody.

(D) IF with control serum as the primary

antibody. The IF with IDDM serum treated slides showed a fluorescent ring, indicating
binding at the cell membrane (arrows), but not in cells treated with any o f the other sera.
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F ig u re 12. Indirect im m unofluorescence showing the IgG binding pattern o f IDDM
serum on N 1E-I15 cells (2). Indirect immunofluorecence was performed on N1E-115
cells using IDDM (A), or control serum (B) as primary antibody and FITC-labeled antihuman IgG as secondary antibody and observed at high magnification. There was light
diffuse fluorescent staining in cells exposed to control serum (B). In contrast, cells
exposed to IDDM serum showed a specific bright halo of fluorescence (A, arrows),
indicating the recognition o f a cell surface antigen by immunoglobulin IgG in IDDM
serum.
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The results showed a characteristic cell surface binding pattern with a bright rim of
immunofluorescence when cells were labeled with serum from IDDM patients with
neuropathy (Fig. 11-A; Fig. 12-A), indicating specific recognition o f a membrane antigen.
This pattern was not seen in cells treated with control serum (Fig. 11-D, Fig. 12-B) or
NIDDM serum (Fig. 11-C).

Three monoclonal anti-GAD antibodies only show weak

cytoplasmic binding and no cell surface binding ( picture not shown).

Summary
The properties of the cytotoxic factor present in EDDM serum were examined.
These studies indicate that the factor was likely to be an immunoglobulin. The neurotoxic
effect could be reduced by 75% by protein A precipitation.

The cytotoxic factor was

present in the immunoglobulin containing fraction precipitated from EDDM patients' sera,
evidenced by the inhibition o f growth of cells treated with immunoglobulins extracted from
the IDDM sera. Indirect immunofluorescence using IDDM sera showing cytotoxicity as
primary antibody and FITC labeled anti-human IgG as secondary revealed a specific cellsurface

IgG

binding pattern,

further supporting

immunoglobulin IgG binding to the cell surface.

the

hypothesis that there was

Moreover, the cytotoxic effect was

reversed about 2/3 by heat inactivation, suggesting the possible involvement of
complement, but not excluding other heat-sensitive factors.
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CHAPTER IV. STUDIES OF THE MECHANISM OF NEURONAL DEATH
CAUSED BY SERUM OF IDDM PATIENTS

There are two forms of cell death with very different characteristics, i.e., necrosis
and apoptosis.

These differ both morphologically and biochemically. Apoptosis is an

active process of neuronal cell death with specific, defining morphologic and molecular
features, such as cell shrinkage with preservation o f organelles, membrane blebbing,
condensation of cytoplasm, compacting of chromatin, fragmentation of DNA into
oligomers, detachment from surrounding cells and the formation of apoptotic bodies
(Carson, 1993). Necrosis is an event with passive cell swelling, membrane lysis and rapid
collapse of internal homeostasis.

Apoptosis as a mechanism of cell death has been

suggested in many neurodegenerative diseases.
In previous studies, we found that serum from EDDM patients inhibited N IE -115
cell growth and differentiation as well as caused cell death in some cases. In attempting to
define the mechanism and events leading to neuronal death induced by EDDM patient
serum, we examined the morphologic, biochemical and genomic DNA change and
intracellular Ca2+ change of N1E-115 cells after exposure to EDDM serum.

Further, we

tested one regulator of apoptosis, Fas/APO-1, as a mediator of the apoptotic effects
observed in response to IDDM sera.

4.1.

Morphology change of NIE-115 cells after exposure to IDDM serum
We previously observed that some sera o f IDDM patients with neuropathy induce

N IE-115 neuroblastoma cell death as early as 4 hr. Furthermore, after exposure to sera
from EDDM patients, the morphological changes o f NB cells under phase contrast
microscopy showed eccentric cytoplasmic condensation, cell shrinkage and lifting from
attachment. Some cells had an intact membrane ballooned around the condensed cytoplasm,
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F igure 13. Morphology change of N IE -115 cells after exposure to IDDM serum. N IE 115 neuroblastoma cells were split and grow n in DMEM medium with 10% serum from
control subjects (A) or IDDM patients (B). A fter exposure to serum from an IDDM
patient, the morphological changes o f NB cells under phase contrast microscopy show
eccentric cytoplasm ic condensation, cell shrinkage and lifting from attachm ent (all
indicating an apoptotic cell death).

Som e cells have intact cell m em brane around

condensed cytoplasm (arrow).
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all suggesting apoptotic cell death (Fig. 13).
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The viable cell number was reduced

significantly as counted with trypan blue exclusion criteria, indicating some manner of cell
removal or death. It should be noted that the number of viable cells might be overestimated
by this procedure, due to the intact cell membranes of apoptotic cells, which would also
exclude trypan blue and could be counted as viable.

4.2. Intracellular calcium change induced by IDDM serum
One o f the early cellular changes described with apoptosis is a rise in intracellular
Ca2+. To measure the changes o f intracellular free calcium in response to IDDM serum,
106NB cells/ml were loaded with the fluorescent intracellular calcium indicator, Fura-2
(5uM final conc.), mixed with pluronic acid (0.02%) to facilitate entry into the cell. After
incubation at 37°C for 60 min, extracellular dye was removed by centrifugation and the NB
cells were resuspended in PBS buffer with 1% bovine serum albumin. An aliquot of cells
was added to a cuvette, which was constantly stirred, and measurements were taken by
alternate excitement with 340nm and 380nm light and emission read at 540nm.

The

sensitivity of Fura-2 loaded NB was checked with histamine and calibrated for minimum
and maximum fluorescence during each experiment. Serum from IDDM, NIDDM and
control subjects was added directly to the cuvette, individually at 15% final concentration.
The emission was recorded for 5-10 min and then analyzed and graphed using the software
SPEX-DM 3000 according to the equations of Grynkiewicz et al, (1985). Results showed
that five o f the eight IDDM sera caused a sustained increase o f intracellular calcium
concentration, starting within 10 seconds after the initial exposure to IDDM serum and
continuing to increase at least up to 10 min (Fig. 14; Fig. 15. 1-4), while with most control
sera (4/5), there was an early peak and then return to base line (Fig. 15. 5-6). There was a
significant (Chi-square, p< 0.05) difference in the frequency of increased intracellular Ca2+
in response to sera from the IDDM and control groups.

The early transient peak was

considered to be an artifact o f adding serum. These results suggested that the elevation of
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F igure 14. Intracellular calcium changes induced by IDDM serum (1). Typical patterns
o f cytosolic free calcium change in response to IDDM and control serum in NB cells
loaded with the intracellular calcium indicator, Fura-2 are shown in this and figure 16.
Results showed that five o f the eight IDDM sera caused a sustained increase of
intracellular calcium concentration, starting within 10 seconds after the initial exposure to
IDDM serum and continuing to increase at least up to 10 min, while w ith most control
sera (4/5), there was an early transient peak and then concentrations returned to baseline.
This was a significant (Chi-square, p< 0.05) difference in the frequency of increased
intracellular Ca2+ in response to serum from the IDDM and control groups.
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F ig u re

15. In tracellu lar calcium changes induced by IDDM serum (2).

The

representative changes o f cytosolic free calcium in response to IDDM serum (1-4) and
control serum (5-6) in NB cells loaded with the intracellular calcium indicator, Fura-2
were show n. ID D M sera caused a sustained in crease o f intracellular calcium
concentration, starting 10 seconds after initial exposure to IDDM serum and continuing to
increase up to 10 m in (1-4), while with control sera, there was an early peak and then a
return to base line (6) or a sustained reduction in intracellular calcium (5).
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intracellular calcium may play a role in the process of cell death by apoptosis.

4.3. Examine genomic DNA fragmentation of NIE-115 ceils after exposure
to IDDM serum
IDDM sera

showing

cytotoxicity to neuroblastoma cells were

neuroblastoma cell cultures as 15% in DMEM.

added

to

Suspended and attached cells were

collected separately at 30 min, 1 hr, 2 hr, 4 hr, 8 hr, 12 hr after exposure to IDDM serum.
The genomic DNA from cells collected at each time point was isolated with a gentle process
using a Micro TurboGen kit (Invitrogen, San Diego). The cells were Iysed with lysing
buffer and RNase solution from the kit. After the lysates were incubated at 65°C for 5
minutes, the protein fraction was precipitated by adding chloroform and separated from the
aqueous layer containing DNA by centrifugation. The DNA was precipitated, washed and
quantitated, and finally resuspended in pH 8.0 TE (Tris-EDTA) buffer.

The purified

genomic DNA was separated by electrophoresis on 1% agarose gel and stained with
ethidium bromide. The gel was examined under ultraviolet illumination to check for the
DNA pattern. The genomic DNA of cells treated with control serum was purified and run
on gel electrophoresis in parallel.

Results showed that a DNA fragmentation ladder, a

marker o f apoptotic cell death, was revealed from suspended cells (Fig. 16, A lanes) as
early as 4 hr after NB cell exposure to cytotoxic EDDM serum. The DNA fragmentation
patterns and time o f appearance were similar for the IDDM sera tested (F ig .l6 -A and B,
lanes A). The cells retaining attachment show no pattern of DNA fragmentation (Fig. 16-A
and B, B lanes) reflecting a non-apoptotic state.

4.4. Studies of apoptosis-related proteins (Fas, p75) expression in NIE115 NB cells
Indirect immunofluorescence (IF)
IF was performed to examine the expression of the apoptosis-related proteins
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F igure 16. C ellular D N A fragm entation ladder o f N IE -115 cells induced by IDDM
serum. IDDM serum show ing cytotoxicity to neuroblastom a cell was added to a set of
neuroblastom a cell cultures as 15% in DMEM. Suspended and attached ceils were
collected separately at 30 min, 1 hr, 2 hr, 4 hr, 8 hr, 12 hr. The genomic DNA was
isolated at each time point and separated by electrophoresis on a 1% agarose gel. A lanes
were DNA extracted from suspended cells and B lanes were D NA extracted from
attached cells. A DNA fragmentation ladder, characteristic o f apoptotic cell death, was
revealed in cells that have lost attachm ent as early as 4 hr after NB cell exposure to
cytotoxic IDDM serum but not with control serum. The D N A fragmentation ladder was
shown in suspended cells but not attached cells. The DNA fragmentation pattern and time
course are similar with two individual IDDM sera.
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Figure 17. Indirect immunofluorescence detecting Fas expression and changes in N1E115 cells. Photomicrographs of indirect immunofluorescence using hamster anti-mouse
Fas monoclonal antibody (mAb) (M BL RK8) as primary antibody and FITC labeled anti
mouse IgG secondary antibody are shown. The results demonstrate that Fas is expressed
on the N IE-115 NB cell surface (a) as well as on differentiated N IE-115 NB cells (b,
arrows). The surface staining pattern is totally blocked by IDDM serum (c), suggesting
that Fas might be one of the surface antigens recognized by immunoglobulin from IDDM
serum (c). Fas staining on NB cells showed a cluster pattern after culture with IDDM
serum 24 hr prior to fixation (d). The residual yellow fluorescence is autofluorescence
from the cell nuclei.
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(Fas, p75> bcl-2, p53) and their possible change in N1E-115 cells after exposure to IDDM
serum. p75 and bcl-2 were expressed weakly on N1E-115 cells (data not shown), while
Fas was strongly expressed on the cell surface (Fig. 17). Because Fas was known as a
surface receptor mediating apoptotic cell death, w e hypothesized that IDDM serum might
induce cell death through a death signal from Fas. W hether the toxic factor in IDDM serum
might block anti-Fas antibody binding to the cell surface was also examined.

The

procedure of immunofluorescence was performed as described before. Briefly, N1E-115
cells were plated at 104 cells in 35mm2 tissue culture dishes on sterile coverslips and grown
for 2 days. The cells were fixed in 4% paraformaldehyde in PBS for 60 min, blocked by
10% mouse serum in PBS for 30 min, incubated with a 1:100 dilution of hamster anti
mouse Fas (M BL, RK8) serum for 60 min, washed 3 times with PBS and exposed to
secondary fluorescent isothiocyanate (FITC)-labeled mouse anti-hamster IgG secondary
antibody (Pharmingen, San Diego) for 30 min.

After immunostaining, the cells were

mounted on slides using o-phenylenediamine (lm g x m l'*) in 90% glycerol and examined
by fluorescence m icroscopy. To examine whether IDDM serum blocked anti-Fas mAb
binding, fixed NB cells were first exposed to IDDM serum for 30 min then to the anti-Fas
mAb and FITC-Iabeled secondary antibody. To examine the change of Fas expression on
NB cells after culture with IDDM serum, the NB cells were cultured in DMEM containing
10% IDDM serum for 24 hr, then IF was performed.
The immunofluorecence studies revealed that Fas was expressed on the N1E-115
NB cell surface in a characteristic non-homogeneous staining pattern (Fig.l7-a). Fas was
also expressed on differentiated N1E-115 NB cells, which were induced to differentiate by
culture in serum free media for 24 hr (Fig. 17-b). The surface staining pattern with antiFas mAb was completely blocked by cytotoxic IDDM serum, suggesting that Fas might be
one of the surface antigens recognized by IDDM serum (Fig. 17-c).

After NB were

cultured in DMEM media with 10% IDDM serum for 24 hr, Fas staining on NB cell
showed a clustering pattern, indicating possible cross-linking by antibody or soluble Fas

*
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ligand in IDDM serum, a prerequisite for Fas activation and apoptosis.
Expression o f p75 was also examined by IF in N 1E-I15 NB cells.

For p75

detection, anti-p75 monoclonal antibody was obtained from Boehringer Mannheim
Biochemica (Indianapolis, IN).

However, there was only a weak fluorescence signal

observed (results not shown).

p53 expression was abundant in the cell nucleus and

perinuclear cytoplasmic region with IF (results not shown), but because o f the cytoplasmic
localization of this nuclear protein, the significance was uncertain. Because N1E-115 cell is
a tumor cell line, the p53 could be mutated causing inactivation and dislocated from of the
nuclear to the cytoplasm region. Bcl-2 expression was not detectable in this cell line either
in proliferating or differentiating stages.

N IE-115

cell

membrane

protein

extraction,

immunoprecipitation

and

Western blotting
Protein chemistry techniques were employed to confirm the presence of Fas in NB
cells.

NB cells (107) were lysed by nitrogen cavitation (PARR Instrument Company,

Moline, IL) in PBS.

Cell membrane and cytosol fractions were separated by gradient

centrifugation. The tissue homogenate was first centrifuged at 500 x g to remove crude
nuclear material, then 10,000 x g to remove mitochondria and 100,000 x g for 60 min to
get the microsomal fraction containing cell membranes. Membrane protein fractions were
solubilized with 1% Triton-XlOO detergent in buffer containing 150mM NaCl, lOmM Tris
pH7.4, ImM EDTA, Im M EGTA, 0.2mM sodium vanadate and 0.5%NP-40 (Tiruppathi,
1986) and the protein content was quantitated with a Micro BCA Protein Assay kit (Pierce
Co., IL). Fifty pi of total lysate containing 100 pg of membrane protein fractions were
mixed with 10 pi of anti-Fas mAb (MBL, RK8 clone about 5 pg) at 4°C for 30 min
followed by 50 pi of 10% protein A beads for 30 min. The protein A beads were spun
down and washed with PBS for 3 times, then the pellet was resuspend in electrophoresis
sample buffer, and boiled for 5 minutes. The supernatant was loaded onto a 12% SDS-
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polyacrylamide gel. After Coomassie blue staining, a major protein band at mouse Fas
MW 40kD a was revealed (Fig. 18-A).
For Western blotting, the NB cell membrane proteins and whole cell homogenates
were solubilized with 1% Triton-XlOO detergent in buffer containing 150mM NaCl, lOmM
Tris pH7.4, Im M EDTA, Im M EGTA, 0.2mM sodium vanadate and 0.5% NP-40 for 30
min, and the protein content was quantitated with the Micro BCA Protein Assay kit (Pierce
Co., IL). Fifty p.1 total lysate containing 100 pg membrane protein fractions were mixed
with 100 pi o f IDDM serum at 4°C for 30 min followed by 50 pi of protein A beads for 30
min. The protein A beads were centrifuged and washed with PBS 3 times, then the pellet
resuspended in electrophoresis sample buffer and boiled for 5 minutes. The supernatant
was loaded onto a 12% SDS-polyacrylamide gel and separated by electrophoresis, then
transferred to PVDF membrane. The membrane was exposed to anti-Fas monoclonal
antibody (MBL, RK8) at a 1:200 dilution at room temperature (RT) for 30 min and washed
3 times with PBS, then exposed to a secondary peroxidase-labeled anti-IgG secondary
antibody at RT for 30 min and developed by enzyme chemiluminescence (ECL)
(Amersham Life Science, Arlington, IL) with Kodak X-Omat AR5 film (Kodak C o.,
Rochester, NY) (Fig. 18-B). These studies demonstrated that NB cell membrane proteins
and whole cell proteins immunoprecipitated with 3 individual IDDM sera, separated by
SDS-polyacrylamide gel electrophoresis and revealed by Western blot with anti-Fas mAb,
showed Fas protein. The results indicated that Fas could be one of the proteins recognized
by IDDM serum. However, more studies are needed to demonstrate that anti-Fas antibody
or Fas ligands are present in IDDM serum and could cause neural cell death.

The effects of Anti-Fas mAb on neuroblastoma cell growth
If N1E-115 cells express Fas, activating anti-Fas mAb may have an inhibiting or
lethal effect on cell growth in culture.

RK8 anti-Fas mAb, which had been shown to

activate the Fas mechanism in other cells, was added to the N IE -115 cell culture in three
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Figure 18. Im m unoprecipitation and western blot o f Fas from N1E-115 cells.

18-A.

Proteins from the membrane fraction of NB cells were immunoprecipitated with anti-Fas
mAb and run on SDS polyacrylamide gel, showing a m ajor protein band at 40kDa, the
mouse Fas molecular weight. F ig u re 18-B: Proteins from the NB cell membrane and
whole cell preparations were immunoprecipitated with IDDM serum, separated by SDSPAGE and Western blot performed with anti-Fas mAb. Protein in lanes 1, 2/3 and 4 were
precipitated by serum from 3 different patients. Lanes 2 and 3 were precipitated with the
same serum, but perform ed with whole cell protein or m embrane protein as indicated
(WP - whole cell protein; MP - cell membrane protein). Protein recognized by the antiFas antibody was precipitated from NB cells by all 3 IDDM sera tested.
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F igure 19. The effects o f anti-Fas mAb on N1E-115 cell growth. To examine the effects
of anti-Fas mAb on NB cell growth, different doses of anti-Fas mAb (1000 ng/ml, 500
ng/ml, 100 ng/ml) were added to the N1E-115 cell culture media for 72 hr. The number
o f viable cells was determined by trypan blue exclusion criteria as described before. The
maximal dose o f anti-Fas mAb (1000 ng/ml) had 49.3% inhibition compared with 10%
FBS control.
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doses (100 ng/ml, 500 ng/ml and 1000 ng/ml). Anti-Fas mAb caused the loss o f NB cells
in a dose-dependent manner within 72 hr of culture. The maximal dose of anti-Fas mAb
(1000 ng/ml) had 43.8% inhibition compared with control (Fig. 19). This observation
further supported the presence of membrane-bound Fas on NB cells and the possibility that
anti-Fas antibody in IDDM serum could cause inhibition o f cell growth.

Summary
Apoptosis as the possible mechanism o f neuronal death induced by IDDM serum
was examined in the N1E-115 NB cell model. The morphological change of NB cells after
exposure to IDDM serum exhibited a characteristic apoptotic cell death pattern: cytoplasmic
condensation, cell shrinkage and lifting.

A DNA fragmentation ladder, a marker of

apoptotic cell death, was evident within 4 hr after exposure to cytotoxic IDDM serum. A
sustained increase in intracellular calcium concentration was noted in the presence of 5 of 8
IDDM sera in Fura-2 loaded NB cells, also characteristic of apoptosis.

These

investigations support the hypothesis that the death o f NB cells caused by IDDM serum
occurred by a mechanism of programmed cell death.
Apoptosis-related protein, including Fas and p75 expression in N1E-115 cells was
examined. Fas was expressed on the NB cell surface in a characteristic non-homogeneous
distribution, as determined by immunofluorescence staining with anti-mouse Fas mAb.
The low affinity NGF receptor, p75, was expressed weakly in N1E-115 cells.
Immunoprecipitation of cell membrane protein with anti-mouse Fas mAb revealed a major
protein band o f M W 40kDa, approximately the size o f murine Fas. Cell-surface membrane
immunofluorescence staining by anti-Fas antibody was completely blocked by IDDM sera
which were previously shown to induce apoptotic neuronal death. Fas distribution on the
cell surface was found in a clustering pattern after 24 hr in culture with IDDM serum,
which may indicate activation of Fas receptors by cross linking with anti-Fas antibody or
soluble Fas ligand in IDDM serum.

Anti-Fas mAb inhibited NB cell growth in a dose

4
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dependent manner. The maximal dose o f anti-Fas mAb (1000 ng/ml) had 43.8% inhibition
compared with control. The studies indicated that Fas could be one o f the cell surface
antigens recognized by humoral factors in IDDM serum.

Whether it is the mediator

inducing apoptotic cell death in response to IDDM serum needs to be confirmed.
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CHAPTER V. SUMMARY AND DISCUSSION

Summary
The possibility that autoimmune-related humoral factors contribute as a cause of
diabetic neuropathy was tested by in vitro application of serum from patients with IDDM
and NIDDM to adrenergic murine neuroblastoma cells in culture. In these studies, we have
demonstrated that the serum from patients with IDDM and neuropathy could cause inhibition
of growth and differentiation in N1E-115 neuroblastoma cells and, in some cases, induced
cell death.

The growth-inhibition, or cytotoxic effect, was more prominent in IDDM

patients with neuropathy but varied in IDDM patients with no neuropathic symptoms. This
effect was not reproduced in NIDDM patients with neuropathy, suggesting a heterogeneous
pathogenesis of diabetic neuropathy in these two type of diabetes. The neuronal toxic effect
of IDDM serum could be abolished by pre-absorption with neuroblastoma cells, indicating
that the effect was mediated by humoral factors that could bind to neuroblastoma cells.
The identity of the cytotoxic factor in IDDM patients serum was examined. These
studies indicated that the toxic factor was likely to be an immunoglobulin. The neurotoxic
effect of IDDM serum could be reduced by protein A pre-absorption (the inhibition was
reduced by 3/4 comparing before and after protein A treatment).

An immunoglobulin-

containing fraction of IDDM serum exerted the inhibitory effect when pooled human serum
was added, but not the immunoglobulin containing fraction from NIDDM and control
groups. The cytotoxic effect was partially reversed by heat inactivation (which reversed the
inhibiting effect by about 2/3), suggesting the involvement of complement but not excluding
other heat sensitive factors.

However, none o f the treatments could totally reverse the

inhibition, suggesting that multiple mechanisms may be involved.
In our study, examination o f N1E-115 cells with indirect immunofluorescence
using IDDM serum as the primary antibody and FITC-labeled anti-human IgG as secondary
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antibody revealed a specific cell surface binding pattern even when the serum was diluted
from 1:50 to 1:200 (F ig .ll; Fig.12), which demonstrated the binding of immunoglobulin
IgG in IDDM serum to a surface antigen on neuroblastoma cells.
The morphological changes o f the neuronal death caused by EDDM serum, such as
cytoplasmic condensation, cell shrinkage and lifting (possibly caused by cell membrane
blebbing) suggested an apoptotic cell death, which could happen as early as 4 hr after
exposure to IDDM serum. Further study showed that the cell death caused by IDDM serum
was associated with an increased intracellular free calcium concentration within 10 min in
some samples. The cytosolic free calcium rise rapidly, as early as 10 sec after exposure to
IDDM serum and continued to rose for up to 10 min. A DNA fragmentation ladder, which
can be found in apoptotic cell death, was observed within 4 hr after exposure to cytotoxic
IDDM serum.

The DNA fragmentation ladder was found in cells that had lifted from

attachment with dishes, but not the cells still attached, suggesting loss o f attachment was
also an early event in apoptotic cell death in vitro. Those unattached cells could be washed
and collected by low speed centrifugation, indicating the integrity o f the membranes was still
intact.
Selected classic apoptosis-related proteins, p75, Fas, bcl-2 and p53, were examined
in this cell line. NGF low affinity receptor p75 was too weakly expressed in NB cells to
evaluate.

However,

immunofluorescence

with

anti-mouse

Fas

mAb

and

immunoprecipitation with anti-Fas mAb indicated Fas antigen was expressed on the surface
of N1E-115 NB cells. The cell- surface Fas immunoflurescence binding pattern was totally
blocked by IDDM serum, indicating that Fas might be one surface antigen recognized by
IDDM serum. The results from immunoprecipitation with IDDM serum followed by
Western blot (Fig. 19-B) further supported the possibility that Fas antigen was recognized
by humoral factors in IDDM serum and was potentially involved in serum toxicity.

*
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Discussion
Antibodies against different neuronal tissue components have been reported in many
neurodegenerative

diseases.

However,

m ost

studies

have

only

demonstrated

immunoglobulin binding in neuronal tissues, or that there was a higher titer of antibodies
against neuronal antigens in the circulation o f neuropathy patients.

It has been unclear

whether these antibodies truly play a primary role in causing neuronal tissue damage or
whether they are a secondary response, resulting from the exposure of neuronal antigen by
damaged tissue.

Furthermore, another question is: "what might the mechanism be of

neuronal tissue damage by these antibodies?"

Neuronal cell culture of N1E-115 cells

provided a model to study both the toxic potential o f serum as well as the mechanism of
neuronal death induced by humoral factors in IDDM serum.
This study demonstrated that humoral factors such as immunoglobulins in EDDM
patients' sera could inhibit neuronal cell growth and differentiation, indicating humoral
immune components could directly cause neuronal target tissue damage, even though
activation o f humoral immune components could be a secondary response to unknown
stimulation. However, none of the studies o f immunoglobulin effects, such as protein A
precipitation to remove immunoglobulins, heat inactivation o f complement or testing the
effect of an immunoglobulin-containing fraction on cell growth, could completely (>75% )
account for the cytotoxic effect of IDDM serum.

Therefore, other possible contributing

factors, such as low levels o f neurotrophic growth factors in the serum of IDDM patients or
activation of the programmed cell death pathway by another initiator, should also be
considered.
The different effects of sera on neuronal cell growth and differentiation between
IDDM and NIDDM patients with neuropathy support the possible role of humoral
immunopathogenesis in neuropathy of IDDM patients, but not NIDDM.

If the humoral

factors, such as anti-neuronal tissue antibodies, w ere a secondary manifestation because of
neuronal tissue destruction and antigen exposure, the test results should be expected to be
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the same in IDDM and NIDDM patients with neuropathy. These inhibitory or toxic effects
were more prominent in IDDM patients with neuropathy, but inconclusive in IDDM
patients with no neuropathy. One explanation was that the patients were in different stages
o f neuronal damage with the non-symptomatic patients in a "pre-neuropathic" stage. They
had not yet had sufficient neuronal loss to cause symptomatic neuropathy. Inhibition was
not reproduced in NIDDM patients with neuropathy, suggesting a possible heterogeneous
pathogenesis o f diabetic neuropathy in the two type o f diabetes.
These studies indicate that the EDDM serum exerted cytotoxic effects on N1E-115
neuroblastoma cells by activation of a programmed cell death cascade, apoptosis.

From

temporal analysis in this model, cytosolic free calcium elevation preceded DNA
fragmentation and cell death. Intracellular calcium elevation had been hypothesized to be an
early primary event in both programmed cell death and hypoxic-ischemic neuronal injury
(Kirino, 1994). The consistent finding that IDDM serum caused an increase in cytosol free
calcium concentration followed by apoptotic cell death, indicated that calcium ion plays a
critical role in the neurotoxic effect. Increasing evidence indicates that calcium could activate
latent enzymes that can contribute to the structural changes o f apoptosis (Jones et al, 1989;
Trump et al, 1992). These enzymes include a calcium-dependent nuclear endonuclease that
can cleave DNA, and a transglutaminase that can crosslink cytosolic proteins. Calciumdependent proteases may also degrade the cytoskeleton. All of the enzymes together appear
to be responsible for nuclear degradation and cell morphology change. It has been reported
that IgM autoantibody in IDDM serum can interact with L-type C a2+ channels to increase
C a ' influx and cause apoptotic cell death in insulin-secreting cells (Berggren et al., 1993).
It remains to be determined in our model that the increased cytosolic calcium was induced by
immunoglobulin (IgG or IgM) and whether the increased cytosolic calcium stimulated by
IDDM serum resulted from calcium influx through membrane calcium channels or a release
from intracellular calcium stores.

Different calcium channel blockers can be studied to

determine the type of calcium channel involved and their possible role in apoptotic cell

*
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death.
Homeostasis of multicellular organisms can be controlled not only by the
proliferation and differentiation o f cells but also by cell death.

Recent evidence clearly

indicates that apoptosis may be positively or negatively regulated by certain genes.

Many

growth factors and hormones could regulate cell survival, growth or differentiation.
Otherwise, cytokines such as Fas ligand or TNF as well as proto-oncogene products and
transcription factors like c-mys, c-fos, c-jun, p53, bcl-2 may regulate or signal the intrinsic
cell death program by inducing or inhibiting apoptosis, which functions to remove
unwanted or non functional cells (Pandey, 1995). Abnormality in the regulation of the cell
death program may contribute to the pathogenesis o f many neurodegenerative diseases,
autoimmune or neoplastic diseases.
Fas/APO-1, a type I cell surface receptor signaling apoptotic cell death pathway, is
expressed in many cell lines and mediates apoptosis of susceptible target cells (Weller et al,
1994). Fas/Fas ligand interaction serves as an important regulatory mechanism in the
development and function of the immune system. Most studies on Fas show Fas-mediated
apoptosis in the cytotoxicity of susceptible T-lymphocytes, suggesting that Fas might play a
critical role in the effector phase of T-dependent immune responses (Hanabuchi et al, 1994).
Some grow th factors and hormones, when bound to their receptors, induce dimerization
(homodimerization or heterodimerization), which then triggers an intracellular signaling
cascade with subsequent gene expression.

Similarly, the apoptotic cell death-signaling

pathway from Fas requires the cross-linking of Fas receptors, either with specific antibodies
to Fas or by Fas ligand trimerization.

This is consistent with our observations of Fas

localization on NB cells treated with cytotoxic IDDM sera.
In our immunocytochemistry study, the cluster of Fas antigen expression on NB
cells surface in response to IDDM serum stimulation might represent Fas molecular crosslinking by the toxic factor in IDDM serum , inducing the cell apoptosis cascade. Treatment
with anti-Fas mAb caused cell death in a dose-dependent fashion, supporting the hypothesis
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that anti-Fas antibody could induce cell death.

Whether Fas expression in NB cells was

altered by exposure to IDDM serum or there was increased circulating Fas ligand in IDDM
serum remains to be determined. The observation that Fas receptor is expressed on the
N1E-115 cell surface and is possibly recognized by IDDM serum suggests that Fas could be
one of the cell surface antigens recognized by the cytotoxic factor in IDDM serum and
thereby mediate apoptotic cell death.
Fas antigen expression has not been reported in neurons and has not been
examined in adrenal medulla, although Fas antigen has been described in some tumor cell
lines (Yonehara, 1989) and satellite cells of the autonomic ganglia (Owen-Schaub et al.,
1993).

Fas was found in brains o f patients with Alzheimer-type dementia, mainly

expressed by a subset of reactive astrocytes.

Such astrocytes may undergo the Fas-

mediated apoptotic process (Nishimura et al., 1995). The existence and the role of Fas in
neuronal cell death induced by IDDM serum needs to be further confirmed.

Fas is a

member of the NGF receptor/TNF receptor family, which all have a cysteine-rich
extracellular domain. It is unclear whether the anti-Fas monoclonal antibody will cross
react with other members in the NGFR/TNFR family on N1E-115 cells because o f the
homology of the extracellular domain and thereby induce cell death, also creating a link
between the hypothetical apoptotic mechanism and the growth factor deficiency.
We were unable to detect bcl-2 in N IE -115 cells by immunofluorescence. The
apparent lack o f bcl-2 in the NB-cell line might simply reflect the lack o f bcl-2 in
neuroblastomas, its replacement by another member of the bcl-2 family, eg, bcl-X, or it may
result from gene loss during tumorigenesis.

Furthermore, the lack of bcl-2 may be

associated with an increased propensity for apoptosis in this cell line. p53 was abundant in
this cell line as indicated by immunofluorescence, but cytoplasmic distribution raises
questions about detection o f this nuclear protein.

However, it is also possible that p53

could be mutated because the N1E-115 cell line is an adrenergic cell clone derived from a
neuroblastoma tumor (Amano et al, 1972).
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Our study cannot exclude the possibility that other unknown antigens or death
factors, such as p75 low affinity NGF receptor, or TN F and its receptors, might also be
involved. Thus, their role, if any, in the apoptotic neuronal death induced by IDDM
humoral factors remains to be elucidated. The low-affinity NGF receptor, p75, appears to
be important for neuronal cell death and survival (Rabizadeh et al., 1993). p75 has some
sequence similarity to the tumor necrosis factor receptors (TNFR-I and TNFR-II), the
human cell surface antigen Fas (APO-1), and the B cell antigen CD40, all of which mediate
cell death through an intracellular "death domain" (Bazzoni, 1996).

Lowering of N G F

concentration, overexpression o f p75, or expression o f less trkA, the high affinity NGF
receptor, causes p75 to signal death (Finkel 1996). The type of cell death induced by p75 is
apoptosis, and neural cell survival is enhanced by binding of NGF to p75 (Rabizadeh et al.,
1993). Recent studies have further supported the concept o f p75 as a constitutive regulator
of apoptosis and suggested that inhibiting p75 expression with antisense oligonucleotides
can rescue neurons from death (Finkel, 1996).
detected weakly, while in preliminary studies
immunofluorescence assay.

In the N1E-115 cell model, p75 was
trkA expression was strong with

More sensitive and quantitative methods will be required to

examine the possible change of p75 or trkA in response to diabetic sera and their role, if
any, in induction of apoptosis by IDDM sera.
These studies demonstrated that serum of EDDM patients with neuropathy had a
greater ability to inhibit neuronal cell growth and differentiation and in some cases induced
cell death in cultured adrenergic neurons. They indicates that autoimmune-related humoral
factors inducing apoptotic neuronal death could be one mechanism involved in the
pathogenesis of diabetic neuropathy. Other investigators have confirmed the appearance o f
autoantibodies before clinical presentation, thus, progressive target cell destruction may
develop over several years (Boitard, 1992). On this basis, it may be possible to identify
individuals at high risk for development of IDDM and its complications using specific
genetic and immunological assays, including the N1E-115 cell model.
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possibility that effective immunotherapies could be developed to prevent the target cell
destruction, while the individual still has substantial target cell reserves.

As mentioned

before, autoantibodies against neuronal tissue may not be correlated with islet cytoplasmic
antibodies (ICA). A method to predict diabetic neuropathy with a more specific neuronal
cell model may provide a more sensitive, earlier and more accurate diagnosis.
Because the N IE -115 neuroblastoma cell line revealed a neurotoxic effect in
response to antibodies in IDDM serum, which was correlated with a diagnosis of clinical
neuropathy and was significantly different from the results in response to NIDDM and
control serum, this cell culture model might allow early prediction and immunotherapy for
prevention of diabetic neuropathy. This cell line may also prove to be a useful model to
further study the mechanism o f neuronal death, autoimmune pathogenesis and may allow
studies of the possible neuronal protective effect o f new drugs, neurotrophic factors like
NGF and to evaluate immune therapy intervention, like intravenous immunoglobulin, for
treatment o f diabetic neuropathy. It is possible in the N IE -115 cell assay that those IDDM
patients without clinical neuropathy symptoms, but whose sera exhibit neurotoxicity, are in
a pre-neuropathic state. Thus, this assay may identify those patients at risk for developing
symptomatic neuropathy.

Further longitudinal studies would help to establish the

significance o f these findings.

Supporting the possibility that autoimmunity might be

important in the pathogenesis o f diabetic neuropathy was the observation that N1E-115
cytotoxicity correlates with symptomatic improvement in patients treated with intravenous
immunoglobulin (IVIg), which has been studied by other investigators in our research
institutes (unpublished data).
The N1E-115 cell model, like all in vitro cell culture systems, is an advance in
cellular level biomedical research. It provides a living model to study and observe changes
of cell morphology, grow th, differentiation and related regulating mechanisms in both
physiological and pathological conditions.

The significance of this study lies in

determining that humoral immune components in sera of IDDM patients can inhibit
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neuronal cell growth and differentiation inhibition and result in cell death, possibly through
inducing

apoptosis.

The

difference

between

these

studies

and

most

other

immunopathogenesis studies in neuropathy is that the others showed that antibodies could
recognize neuronal tissue but could not demonstrate that these antibodies actually damage
neuronal tissue. In contrast, in the N1E-115 cell model we have shown both neuronal
toxicity and immunoglobulin causation.
However, the N1E-115 neuroblastoma cell line is a murine tumor cell line. Its
regulating machinery for cell growth and differentiation might already be altered.

Some

oncogenes could be constitutively turned on while others could be mutated or deleted.
Another disadvantage is that the sera tested are an unknown mixture.

There are

components which could influence the growth and differentiation of the cells but may not
be related to diabetes and with varying quantities in the serum among individuals. Thus we
could not control for all effects of serum in the model. Finally, this model could not reveal
the possible intrinsic change of diabetic neuronal tissue which may play a role in the
process of immunopathogenesis of diabetic neuropathy, especially in IDDM patients. Only
external effectors could be evaluated in these studies.

Conclusion

• Sera from IDDM patients with neuropathy had a higher frequency to inhibit growth and
differentiation of an adrenergic neuronal cell line, N IE -115 neuroblastoma cells, but
not sera from NIDDM and control subjects. In some cases, the humoral factors in sera
o f IDDM patients with neuropathy induced neuronal death in vitro.
• The neuronal toxicity appeared to be mediated by immunoglobulin in the serum of
IDDM patients and at least partially through a complement-related mechanism.
•

The neuronal death caused by IDDM serum seemed to be an apoptotic cell death, which
is characterized by cell shrinkage, cytoplasmic condensation, cell lifting, increased

•i
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intracellular calcium change and genomic DNA fragmentation.
•

Fas, an initiator of apoptosis, could be one cell surface molecule recognized by humoral
factors in IDDM serum and able to activate the neuronal death pathway.

•

Our study supports the hypothesis that immunopathogenesis may be important in the
development of diabetic neuropathy, thus, indicating that immunotherapy such as IVIg
treatment could be a practical and effective treatment. Other possible strategies based on
autoimmune pathogenesis aimed to block the neuronal death pathway should be
considered and further investigated.

•d
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